Research, Advocacy and Practice: Working Together to Impact Outcomes in Pancreatic Cancer

You need to be logged in to continue. Please Log In or Register using the box at the top right of this page.

Release Date: June 22, 2015
Expiration Date: June 22, 2016

Expected time to complete this activity as designed: 90 minutes

There are no fees for participating in or receiving credit for this online activity.

Program Overview

Many patients consider length of life and quality of life as two of the most important elements for their pancreatic cancer care although each patient’s cancer treatment experience is distinct to the individual. This activity brings together experts in advocacy, research, and practice to share recent progress made in science and practice which are showing a positive impact to overall care and survival. With this information, nurses will be best prepared to assist in the challenging and sometimes painful life decisions faced by this patient population and their caregivers. Watch this session and learn how we can each play a part in positively impacting the care and lives of patients with pancreatic cancer.

Target Audience

This activity is designed for oncology nurses who have an interest in enhancing their clinical skills in the management of pancreatic cancer.

Learning Objectives

Upon completion of this educational activity, participants should be able to:

  • Compare and contrast treatment approaches from resectable to advanced metastatic disease, focusing on the potential survival benefits of each

  • Summarize ongoing clinical trials that are investigating chemotherapeutic and/or immunotherapeutic approaches which may identify how advances impact future treatment paradigms

  • Demonstrate a collaborative team approach to the issue of suboptimal referral to clinical trials, identify those patients who would benefit from participation in a clinical trial, and describe effective patient education and communication strategies

  • Describe the patient and caregiver impact of a shared decision-making model in providing comprehensive supportive care in advanced metastatic pancreatic cancer, and outline an approach designed to support patient participation in the decision-making process


Welcome and Introduction: Progress Report on the Goal to Double Pancreatic Cancer Survival by 2020 – Anitra Engebretson

The Practice of Treating Pancreatic Cancer and Future Directions: Research Update – Eileen M. O’Reilly, MD

Advocacy in Pancreatic Cancer: Shared Decision Making, Empowering the Patient and the Role of the Nurse – Mary Griffin Strom, MSN, RN

Instructions for Participation and Credit

This activity is eligible for credit through June 22, 2016. After this date, this activity will expire and no further credit will be awarded.
1. Read the target audience, learning objectives, and faculty disclosures.
2. You may be asked to complete a short pre-test before accessing the educational content. This must be completed in order to move forward in the activity.
3. Complete the educational content as designed.
4. Complete the post-test. To receive a certificate, you must receive a passing score of 70%.
5. Complete the activity evaluation survey to provide feedback and information useful for future programming.
6. Certificates for CNE may be printed immediately after successfully completing the post-test and activity evaluation.

Faculty Biographies

Eileen M. O’Reilly, MD
Associate Director for Clinical Research
David M. Rubenstein Center for Pancreas Cancer Research
Memorial Sloan-Kettering Cancer Center
Associate Professor of Medicine
Weill Medical College of Cornell University
New York, New York

Dr. Eileen M. O’Reilly received her medical degree at Trinity College (Dublin University) in Ireland. She completed her residency training in Ireland and fellowship training at Memorial Sloan Kettering Cancer Center (MSKCC) in New York City. Dr. O’Reilly is associate director for clinical research at the David M. Rubenstein Center for Pancreas Cancer Research at MSKCC, where she is also an associate member of the in the GI Medical Oncology service. In addition, Dr. O’Reilly is an associate professor of medicine at Weill Medical College of Cornell University.

Dr. O’Reilly is the chair of the NCI Pancreas Task Force, a member of the Alliance GI core committee, and serves on the Scientific Advisory Board of the Pancreatic Cancer Action Network, NCCN Pancreas panel, Board of the National Pancreas Foundation and ASCO IMT committee. In addition, Dr. O’Reilly is the Principal Investigator of multiple phase I, II and III trials in pancreas cancer, and has authored/co-authored approximately 180 articles, editorials and book chapters. Dr. O’Reilly’s major research focus is pancreatic and hepatobiliary malignancies, and her research initiatives include integration of molecular and genetic-based therapies for the treatment of pancreas cancer, along with development of adjuvant and neoadjuvant therapies and identification of biomarkers that may be used to select therapy.

Anitra Engebretson
Patient Services & Medical Relations
Pancreatic Cancer Action Network
Manhattan Beach, California

Anitra Engebretson holds a BS in biology from the University of Minnesota and has extensive experience in the field of patient education and advocacy, as well as program development. As director of Patient Services & Medical Relations, she strives to provide pancreatic cancer patients, caregivers, and their family members with extensive support and knowledge with the goal of helping them become empowered through education to understand all of their options. Ms. Engebretson is committed to driving medical progress to improve patient outcomes. She works in a collaboration with key health care professionals throughout the nation to bring relevant and medically accurate information and services to the pancreatic cancer patient community.

Under her leadership, the Patient and Liaison Services (PALS) program, which is highly regarded throughout the medical community, has served over 60,000 patients and family members through its call-in information program. Ms. Engebretson is skilled at identifying programmatic challenges and in providing innovative solutions. She has been a driving force toward significant expansion of clinical trial education and awareness.

Mary Griffin Strom, MSN, RN
Creative Health Care Management
Minneapolis, Minnesota

Mary Strom received her BSN and MSN at St. Louis University, Missouri. As a consultant with Creative Health Care Management, she is responsible for working with health care organization leaders to design and implement relationship-based care principles to meet goals and priorities that focus on patient safety, patient experience, and staff engagement. She works with staff and leadership shared governance councils to build infrastructure and outcomes that supports the organizational priorities.

Ms. Strom holds memberships in the American Organization of Nurse Executives, American Cancer Society, and the Oncology Nursing Society. She is a facilitator of Reigniting the Spirit of Caring, an inspirational program that inspires and educates staff in the relationships of self, colleague, and patient/family; Leading an Empowered Organization, a leadership development program, focused on healthy relationships, building capacity, and leading change; as well as for Therapeutic Relationships workshops, focused on clinical professionals understanding of the elements of creating a caring and healing relationship with patients. Ms. Strom is passionate about patient and family involvement in their care, patient safety, and staff engagement that allows for the maximum patient outcome, both clinically and experientially.


MediCom WOrldwide, Inc. NURSING CREDIT
Accreditation Statement: MediCom Worldwide, Inc., 101 Washington Street, Morrisville, PA 19067 is approved by the California Board of Registered Nursing, Provider Number CEP11380. MediCom designates this CNE activity for 1.5 contact hours. Program Number: 15-042-012


As an organization accredited by the Accreditation Council for Continuing Medical Education (ACCME), Accreditation Council for Pharmacy Education (ACPE) and California State Board of Registered Nursing, MediCom Worldwide, Inc. requires everyone who is a position to control the content of an educational activity to disclose all relevant financial relationships with any commercial interest. The ACCME defines “relevant financial relationships” as financial relationships in any amount, occurring within the past 12 months, including financial relationships of a spouse or life partner, that could create a conflict of interest. Accordingly, the following disclosures were made.

Faculty Disclosures

Dr. Eileen O’Reilly has received consultant fees from Aduro Biotech; Array BioPharma; Astellas Pharma US, Inc.; BioAlliance Pharma; Boston Scientific Corporation; Boston Therapeutics, Inc.; Bristol-Myers Squibb Company; CASI, Pharmaceuticals Inc.; Celgene Corporation; Cipla; Eli Lilly and Company; Gilead; IntegraGen; MedImmune, LLC; Merrimack Pharmaceuticals, Inc.; Momenta Pharmaceuticals; Novartis AG; Onxeo; Pharmacyclics, Inc.; sanofi-aventis U.S. LLC; Silenseed LTD; SillaJen Biotherapeutics; and Vicus Therapeutics. She has received grant support related to research activities from Abbott Laboratories; Amgen Inc.; Bayer AG; Celgene; Eli Lilly; Exelixis, Inc.; F. Hoffmann-La Roche Ltd; Genentech, Inc.; ImClone Systems (a wholly-owned subsidiary of Eli Lilly and Company); Immunomedics, Inc.; Incyte Corporation; Momenta; Myriad Genetics, Inc.; Novartis; OncoMed Pharmaceuticals, Inc.; Polaris Group; and Vicus Therapeutics.

Anitra Engebretson and Mary Griffin Strom have disclosed no relevant financial relationships.

Planning Committee Disclosures

The individuals listed below from MediCom Worldwide, Inc. reported the following for this activity: Joan Meyer, RN, MHA, executive director, has no relevant financial relationships.

Peer Reviewer Disclosure

In accordance with MediCom Worldwide, Inc. policy, all content is independently peer reviewed for balance, objectivity and commercial bias. The peer reviewers have no relevant financial relationships to disclose.

Off-Label Disclosures/Investigational Disclosures

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The opinions expressed in the educational activity are those of the faculty. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings. Further, attendees/participants should appraise the information presented critically and are encouraged to consult appropriate resources for any product or device mentioned in this program.

Dr. O’Reilly has indicated that she does intend to discuss off-label uses of drugs, mechanical devices, biologics or diagnostics approved by the US Food and Drug Administration (FDA) for use in the US.

Ms. Engebretson and Ms. Strom have indicated that they do not intend to discuss off-label uses of drugs, mechanical devices, biologics or diagnostics approved by the US Food and Drug Administration (FDA) for use in the US.

Dr. O’Reilly has indicated that she does intend to discuss investigational drugs, mechanical devices, biologics or diagnostics not approved by the FDA for use in the US.

Ms. Engebretson and Ms. Strom have indicated that they do not intend to discuss investigational drugs, mechanical devices, biologics or diagnostics not approved by the FDA for use in the US.

Hardware/Software/Internet Requirements

MediCom Worldwide, Inc. requires Internet Explorer® version 9.0 or higher, the latest version of Google Chrome, or the latest version of Safari, a computer running Windows® Vista, Windows® 7, or Mac OS X, 512MB of RAM or greater, 1.5 GHZ or faster processor, and a screen resolution of 1024x768 or higher. Certain educational activities may require additional software to view. These activities will be marked with the information and/or links to the required software. That software may include Adobe® Flash® Player, Adobe® Acrobat®, Windows Media® Player, and/or Microsoft® Silverlight™.

If you have any questions or concerns regarding this activity, please contact MediCom Worldwide, Inc. at 1-800-408-4242 or email us at

Provided by MediCom Worldwide, Inc.

This activity is supported by an educational grant from Celgene Corporation

©2015 MediCom Worldwide, Inc., 101 Washington St., Morrisville, PA 19067, 800-408-4242.
No portion of this material may be copied or duplicated without the expressed permission of MediCom Worldwide, Inc.

You need to be logged in to continue. Please Log In or Register using the box at the top right of this page.

MediCom Worldwide, Inc. would like to thank Celgene Corporation for their educational support of

©2020 MediCom Worldwide, Inc. All rights reserved